CA2694289C - Polymyxin derivatives and uses thereof - Google Patents

Polymyxin derivatives and uses thereof Download PDF

Info

Publication number
CA2694289C
CA2694289C CA 2694289 CA2694289A CA2694289C CA 2694289 C CA2694289 C CA 2694289C CA 2694289 CA2694289 CA 2694289 CA 2694289 A CA2694289 A CA 2694289A CA 2694289 C CA2694289 C CA 2694289C
Authority
CA
Canada
Prior art keywords
dab
polymyxin
seq
derivative
residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA 2694289
Other languages
English (en)
French (fr)
Other versions
CA2694289A1 (en
Inventor
Martti Vaara
Timo Vaara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Northern Antibiotics Oy
Original Assignee
Northern Antibiotics Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northern Antibiotics Oy filed Critical Northern Antibiotics Oy
Publication of CA2694289A1 publication Critical patent/CA2694289A1/en
Application granted granted Critical
Publication of CA2694289C publication Critical patent/CA2694289C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • C07K7/62—Polymyxins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA 2694289 2006-08-11 2007-08-10 Polymyxin derivatives and uses thereof Active CA2694289C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US83742606P 2006-08-11 2006-08-11
US60/837,426 2006-08-11
DKPA200601055 2006-08-11
DKPA200601055 2006-08-11
PCT/FI2007/050441 WO2008017734A1 (en) 2006-08-11 2007-08-10 Polymyxin derivatives and uses thereof

Publications (2)

Publication Number Publication Date
CA2694289A1 CA2694289A1 (en) 2008-02-14
CA2694289C true CA2694289C (en) 2015-04-07

Family

ID=39032653

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2694289 Active CA2694289C (en) 2006-08-11 2007-08-10 Polymyxin derivatives and uses thereof

Country Status (21)

Country Link
EP (2) EP3078672A1 (enExample)
JP (1) JP5226685B2 (enExample)
KR (2) KR20150008198A (enExample)
CN (2) CN101501063B (enExample)
AU (1) AU2007283514B2 (enExample)
BR (1) BRPI0715095B8 (enExample)
CA (1) CA2694289C (enExample)
CY (1) CY1117848T1 (enExample)
DK (1) DK2057185T3 (enExample)
ES (1) ES2575521T3 (enExample)
HR (1) HRP20160552T1 (enExample)
HU (1) HUE028271T2 (enExample)
IL (2) IL196693B (enExample)
MX (1) MX2009001398A (enExample)
NO (1) NO341982B1 (enExample)
NZ (1) NZ575421A (enExample)
PL (1) PL2057185T3 (enExample)
PT (1) PT2057185E (enExample)
RU (1) RU2455311C2 (enExample)
SI (1) SI2057185T1 (enExample)
WO (1) WO2008017734A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060004185A1 (en) 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
FI20085469A0 (fi) * 2008-02-08 2008-05-16 Northern Antibiotics Oy Polymyksiinijohdannaiset, joissa on lyhyt rasvahappohäntä, ja niiden käyttöjä
TW201035111A (en) 2008-12-23 2010-10-01 Biosource Pharm Inc Antibiotic compositions for the treatment of gram negative infections
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
WO2012051663A1 (en) * 2010-10-21 2012-04-26 Monash University Antimicrobial compounds
BR112014012016A2 (pt) * 2011-11-18 2017-05-16 Cantab Anti-Infectives Ltd compostos
JP6643758B2 (ja) 2013-05-22 2020-02-12 スペロ・セラピューティクス・インコーポレーテッド 異なった抗生物質と一緒の組合せ療法におけるポリミキシン誘導体及びその使用
RU2740190C2 (ru) * 2014-03-11 2021-01-12 Сперо Терапьютикс, Инк. Производные полимиксина и их применение в комбинированной терапии совместно с различными антибиотиками
KR101664106B1 (ko) 2014-09-11 2016-10-10 한국화학연구원 폴리믹신 b 화합물을 포함하는 심혈관 질환의 예방 및 치료용 약학적 조성물
CN107108699A (zh) * 2014-11-26 2017-08-29 新药物许可控股有限公司 化合物
US9771394B2 (en) 2014-12-16 2017-09-26 Micurx Pharmaceuticals, Inc. Antimicrobial polymyxins for treatment of bacterial infections
CN107530397A (zh) * 2014-12-18 2018-01-02 赫尔普百治疗有限公司 新型组合和用途
FI126143B (en) * 2015-01-15 2016-07-15 Northern Antibiotics Oy Polymyxine derivative and its uses
US9763996B2 (en) 2015-01-16 2017-09-19 Northern Antibiotics, Ltd. Polymyxin derivative and uses thereof
CN104672307B (zh) * 2015-03-23 2017-09-29 吉林大学 一种提高阳离子短肽抗菌性和稳定性的方法
EP3072956A1 (en) * 2015-03-25 2016-09-28 Université de Fribourg Selective culture medium for polymyxin-resistant, gram-negative bacteria
FR3036406B1 (fr) 2015-05-20 2019-07-19 Biomerieux Identification des bacteries resistantes aux carbapenemes par impermeabilite membranaire
EP3374027B1 (en) * 2015-11-12 2021-06-23 The Trustees of Columbia University in the City of New York Rational drug design targeting resistant gram-negative bacterial infections to polymyxin-class antibiotics
WO2017189866A1 (en) * 2016-04-27 2017-11-02 Spero Opco Polymyxin analogs useful as antibiotic potentiators
WO2017189868A1 (en) * 2016-04-27 2017-11-02 Spero Opco Serine replacement polymyxin analogues useful as antibiotic potentiators
GB201703898D0 (en) 2017-03-10 2017-04-26 Helperby Therapeautics Ltd Method
GB201704620D0 (en) 2017-03-23 2017-05-10 Helperby Therapeautics Ltd Combinations
AU2018359018B2 (en) * 2017-11-02 2022-11-24 The University Of Queensland Peptide antibiotics
EP3560489A1 (en) * 2018-04-27 2019-10-30 European Molecular Biology Laboratory Pharmaceutical compositions for prevention and/or treatment of infections and antibacterial-induced dysfunctions
MD3810633T2 (ro) 2018-06-25 2024-05-31 Spero Therapeutics Inc Compuşi
CN112739710B (zh) * 2018-07-19 2024-08-27 东北大学 具有抗菌特性的化合物
CN110179967A (zh) * 2019-05-28 2019-08-30 中国医药集团总公司四川抗菌素工业研究所 多粘菌素母核和一种抗生素的组合物及其应用
IT201900025414A1 (it) 2019-12-23 2021-06-23 Univ Bologna Alma Mater Studiorum Composto per il trattamento della sindrome emolitico uremica
WO2021150792A1 (en) 2020-01-21 2021-07-29 Micurx Pharmaceuticals, Inc. Novel compounds and composition for targeted therapy of kidney-associated cancers
CN118028502B (zh) * 2022-08-30 2024-07-26 四川大学华西医院 一类phoQ基因突变体、应用及其验证方法
WO2024123712A1 (en) * 2022-12-04 2024-06-13 Genentech, Inc. Analysis of candidate cytotoxic compositions
CN120399010B (zh) * 2025-07-01 2025-09-12 杭州肽佳生物科技有限公司 抗生素多粘菌素的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3450687A (en) 1966-02-24 1969-06-17 Pfizer & Co C Lower alkanoyl esters of polymyxin antibiotics
JPS4915537B1 (enExample) 1970-03-25 1974-04-16
BE754411A (fr) 1969-08-05 1971-02-04 Rhone Poulenc Sa Cyclopeptides derives des polymyxines et leur
GB2128617A (en) 1982-10-06 1984-05-02 Martti Vaara Polypeptides for use in antibacterial therapy
DE60130359T2 (de) * 2000-11-20 2008-06-26 Daiichi Sankyo Co., Ltd. Deshalogenverbindungen
WO2002055543A2 (en) 2001-01-16 2002-07-18 Univ Ramot Hybrid peptides for treatment of bacteremia and septicemia
DE60217060T2 (de) * 2002-03-01 2007-06-21 Chiesi Farmaceutici S.P.A. Pharmazeutische Zusammensetzungen, die Lungensurfactants und ein Polymyxin umfassen und verbesserte Oberflächenspannung-senkende Eigenschaften haben
US20060004185A1 (en) * 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion

Also Published As

Publication number Publication date
EP3078672A1 (en) 2016-10-12
BRPI0715095B1 (pt) 2018-08-07
NO20090674L (no) 2009-05-08
IL220270A0 (en) 2012-07-31
MX2009001398A (es) 2009-02-17
NO341982B1 (no) 2018-03-05
CN103059106A (zh) 2013-04-24
CN101501063B (zh) 2014-03-12
JP2010500331A (ja) 2010-01-07
WO2008017734A1 (en) 2008-02-14
RU2455311C2 (ru) 2012-07-10
BRPI0715095B8 (pt) 2021-05-25
EP2057185B1 (en) 2016-05-11
CA2694289A1 (en) 2008-02-14
IL196693B (en) 2018-01-31
CN103059106B (zh) 2015-01-14
IL196693A0 (en) 2009-11-18
KR101502453B1 (ko) 2015-03-24
NZ575421A (en) 2011-11-25
PT2057185E (pt) 2016-06-17
HUE028271T2 (en) 2016-12-28
ES2575521T3 (es) 2016-06-29
EP2057185A4 (en) 2009-08-19
DK2057185T3 (en) 2016-06-13
JP5226685B2 (ja) 2013-07-03
EP2057185A1 (en) 2009-05-13
SI2057185T1 (sl) 2016-10-28
CN101501063A (zh) 2009-08-05
BRPI0715095A2 (pt) 2013-10-15
KR20090045932A (ko) 2009-05-08
AU2007283514A1 (en) 2008-02-14
KR20150008198A (ko) 2015-01-21
HRP20160552T1 (hr) 2016-07-15
PL2057185T3 (pl) 2016-09-30
WO2008017734A8 (en) 2009-07-30
AU2007283514B2 (en) 2012-09-06
RU2009107857A (ru) 2010-09-20
CY1117848T1 (el) 2017-05-17

Similar Documents

Publication Publication Date Title
CA2694289C (en) Polymyxin derivatives and uses thereof
US7807637B2 (en) Polymyxin derivatives and uses thereof
US8329645B2 (en) Polymyxin derivatives and uses thereof
CA2713467C (en) Short fatty acid tail polymyxin derivatives and uses thereof
US9090669B2 (en) Short fatty acid tail polymyxin derivatives and uses thereof
US9096649B2 (en) Polymyxin derivatives and uses thereof

Legal Events

Date Code Title Description
EEER Examination request
H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20250212